February 01, 2015 11:57 AM ET


Company Overview of Revalesio Corporation

Company Overview

Revalesio Corporation, a biotechnology company, develops therapeutics for the treatment of inflammatory diseases. It offers respiratory, cardiovascular, neuroscience, orthopedic, wound care, and oncology products. The company was formerly known as Microdiffusion, Inc. and changed its name to Revalesio Corporation in August 2007. Revalesio Corporation was founded in 2000 and is based in Tacoma, Washington.

1200 East D Street

Tacoma, WA 98421

United States

Founded in 2000



Key Executives for Revalesio Corporation

Chairman and Chief Executive Officer
Director of Operations
Director of Clinical Sciences
Compensation as of Fiscal Year 2014.

Revalesio Corporation Key Developments

Revalesio Corporation Appoints Bert van den Bergh as President

Revalesio Corporation announced that the appointment of Bert van den Bergh as President. Mr. van den Bergh brings extensive industry experience to Revalesio as the company accelerates the development and commercialization of its therapeutic, RNS60. He previously spent 30 years with Eli Lilly & Company where he served as President of Neuroscience Products, President of European Operations and General Manager for the United Kingdom and Germany. In addition to his role at Revalesio, van den Bergh serves on a variety of nonprofit boards and advisory committees, including the Pulmonary Vascular Research Institute, Mental Health America and Peers for Progress.

Revalesio Corporation Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich

Revalesio Corporation announced a new collaboration with neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis (RRMS or MS). The study will compare measurements of disease activity and progression in patients with RRMS during 6-months treatment with RNS60. The open label study will enroll 15 patients and evaluate the use of RNS60 by intravenous administration compared to patient's pre-treatment disease activity. The main outcome of the study will be the reduction of inflammatory activity in the brain as measured by Gd contrast-enhacing MRI lesions. Additional measures include progression of disability and biomarkers for RNS60 and general inflammation. The study will be conducted at the University Hospital Zurich in Switzerland and at Innsbruck Medical University in Innsbruck, Austria. RNS60 has been tested in numerous pre-clinical models of MS and has shown the ability to halt disease progression by limiting glial infiltration (inflammation in the brain), protecting myelin and enriching the regulatory T-cell (TREG) populations in animals treated with RNS60.

Similar Private Companies By Industry

Company Name Region
SCILEX Pharmaceuticals, Inc. United States
Ixora Bio Medical Company Inc. United States
Ozelle Pharmaceuticals Inc. United States
MAP Pharmaceuticals, Inc. United States
KareMor International, Inc. United States

Recent Private Companies Transactions

Private Placement
April 21, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Revalesio Corporation, please visit revalesio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.